Related Experiment Video
Updated: Jun 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide
Agnès Depatureaux1, Charlotte Charpentier, Gilles Collin
1Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France.
Abstract:
We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC(50)s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Retroviruses
Inhibitors Of Virion Release
Subviral Agents
Inhibitors of Viral Protein Synthesis

